Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063573 | 0.87 | BACE1 (0.44) | CA1CA2MEN1LMNAKMT2A | |
| SCHEMBL25860654 | 0.82 | PDE4D (0.40) | — | |
| SCHEMBL22063576 | 0.81 | PDE4D (0.48) | SMN1; SMN2TP53 | |
| SCHEMBL25860646 | 0.80 | ALDH1A1 (0.41) | TDP1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL22063759 | 0.77 | ACHE (0.48) | MEN1KMT2A | |
| SCHEMBL22063651 | 0.77 | ALDH1A1 (0.41) | LMNAHTTSMN1; SMN2TP53 | |
| SCHEMBL22063648 | 0.71 | ALDH1A1 (0.40) | SLC6A3SLC6A2SLC6A4CA1CA2 | |
| SCHEMBL7906590 | 0.70 | TSHR (0.54) | SLC6A3SLC6A2SLC6A4CA1CA2 | |
| SCHEMBL7906596 | 0.70 | TSHR (0.54) | SLC6A3SLC6A2SLC6A4CA1CA2 | |
| SCHEMBL7902731 | 0.70 | TSHR (0.54) | SLC6A3SLC6A2SLC6A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | NORTHWESTERN UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691958-B2 | Enantioselective cross dehydrogenative coupling reactions and compounds synthesized by the reactions | DUOX1, DUOX2, ALDH3A1 | SLC6A3 2214/4885SLC6A2 3001/4885SLC6A4 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.